Perrigo buys Crohn’s disease drug for $380 million

  Perrigo will acquire Entocort (budesonide) capsules as well as the authorized generic capsules marketed by Par Pharmaceuticals within the US from AstraZeneca plc for $380 million. Entocort, a gastroenterology More...

RedHill Biopharma Acquires Technology from University of Minnesota

– The University of Minnesota is buying rights for the development of a diagnostic Crohn’s disease test. Israeli RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) , has entered into a license agreement More...

RedHill Biopharma Announces Definitive Agreement for $11.7 Million Private Placement

– Press release TEL-AVIV, Israel, January 14, 2014, RedHill Biopharma Ltd. (NASDAQ: RDHL; TASE: RDHL) (the “Company” or “RedHill”), an emerging Israeli biopharmaceutical company More...